SEARCH

SEARCH BY CITATION

References

  • AREND, W.P., MALYAK, M., GUTHRIDGE, C.J. & GABAY, C. (1998). Interleukin-1 receptor antagonist: role in biology. Annu. Rev. Immunol., 16, 2755.
  • BERDYSHEV, E., BOICHOT, E., CORBEL, M., GERMAIN, N. & LAGENTE, V. (1998). Effects of cannabinoid receptor ligands on LPS-induced pulmonary inflammation in mice. Life Sci., 63, PL125PL129.
  • BOER, R., ULRICH, W.R., KLEIN, T., MIRAU, B., HAAS, S. & BAUR, I. (2000). The inhibitory potency and selectivity of arginine substrate site nitric-oxide synthase inhibitors is solely determined by their affinity toward the different isoenzymes. Mol. Pharmacol., 58, 10261034.
  • CARLISLE, S.J., MARCIANO-CABRAL, F., STAAB, A., LUDWICK, C. & CABRAL, G.A. (2002). Differential expression of the CB2 cannabinoid receptor by rodent macrophages and macrophage-like cells in relation to cell activation. Int. Immunopharmacol., 2, 6982.
  • CHANG, Y.H., LEE, S.T. & LIN, W.W. (2001). Effects of cannabinoids on LPS-stimulated inflammatory mediator release from macrophages: involvement of eicosanoids. J. Cell. Biochem., 81, 715723.
  • CONNELLY, L., JACOBS, A.T., PALACIOS-CALLENDER, M., MONCADA, S. & HOBBS, A.J. (2003). Macrophage endothelial nitric-oxide synthase autoregulates cellular activation and pro-inflammatory protein expression. J. Biol. Chem., 278, 2648026487.
  • COUTTS, A.A., IRVING, A.J., MACKIE, K., PERTWEE, R.G. & ANAVI-GOFFER, S.E. (2002). Localisation of cannabinoid CB(1) receptor immunoreactivity in the guinea pig and rat myenteric plexus. J. Comp. Neurol., 448, 410422.
  • DE WINTER, B.Y., BREDENOORD, A.J., DE MAN, J.G., MOREELS, T.G., HERMAN, A.G. & PELCKMANS, P.A. (2002). Effect of inhibition of inducible nitric oxide synthase and guanylyl cyclase on endotoxin-induced delay in gastric emptying and intestinal transit in mice. Shock, 18, 125131.
  • DEVANE, W.A., HANAUS, L., BREUER, A., PERTWEE, R.G., STEVENSON, L.A., GRIFFIN, G., GIBSON, D., MANDELBAUM, A., ETINGER, A. & MECHOULAM, R. (1992). Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science, 258, 19461949.
  • FARQUHAR-SMITH, W.P., JAGGAR, S.I. & RICE, A.S. (2002). Attenuation of nerve growth factor-induced visceral hyperalgesia via cannabinoid CB(1) and CB(2)-like receptors. Pain, 97, 1121.
  • GALLILY, R., YAMIN, A., WAKSMANN, Y., OVADIA, H., WEIDENFELD, J., BAR-JOSEPH, A., BIEGON, A., MECHOULAM, R. & SHOHAMI, E. (1997). Protection against septic shock and suppression of tumor necrosis factor alpha and nitric oxide production by dexanabinol (HU-211), a nonpsychotropic cannabinoid. J. Pharmacol. Exp. Ther., 283, 918924.
  • GATLEY, S.J., GIFFORD, A.N., VOLKOW, N.D., LAN, R. & MAKRIYANNIS, A. (1996). 123I-labeled AM251: a radioiodinated ligand which binds in vivo to mouse brain cannabinoid CB1 receptors. Eur. J. Pharmacol., 307, 351358.
  • GRIFFIN, G., FERNANDO, S.R., ROSS, R.A., MCKAY, N.G., ASHFORD, M.L., SHIRE, D., HUFFMAN, J.W., YU, S., LAINTON, J.A. & PERTWEE, R.G. (1997). Evidence for the presence of CB2-like cannabinoid receptors on peripheral nerve terminals. Eur. J. Pharmacol., 359, 5361.
  • HANES, L., BREUER, A., TCHILIBON, S., SHILOAH, S., GOLDENBERG, D., HOROWITZ, M., PERTWEE, R.G., ROSS, R.A., MECHOULAM, R. & FRIDE, E. (1999). HU-308: a specific agonist for CB(2), a peripheral cannabinoid receptor. Proc. Natl. Acad. Sci. U.S.A., 96, 1422814235.
  • HELLSTROM, P.M., AL-SAFFAR, A., LJUNG, T. & THEODORSSON, E. (1997). Endotoxin actions on myoelectric activity, transit, and neuropeptides in the gut. Role of nitric oxide. Digest. Dis. Sci., 42, 16401651.
  • HERKENHAM, M., LITTLE, A.B., JOHNSON, M.R., MELVIN, L.S., DE COSTA, B.R. & RICE, K.C. (1990). Cannabinoid receptor localization in the brain. Proc. Natl. Acad. Sci. U.S.A., 87, 19321936.
  • HILLARD, C.J., MANNA, S., GREENBERG, M.J., DICAMELLI, R., ROSS, R.A., STEVENSON, L.A., MURPHY, V., PERTWEE, R.G. & CAMPBELL, W.B. (1999). Synthesis and characterization of potent and selective agonists of the neuronal cannabinoid receptor (CB1). J. Pharmacol. Exp. Ther., 289, 14271435.
  • HOSOHATA, K., QUOCK, R.M., HOSOHATA, Y., BURKEY, T.H., MAKRIYANNIS, A., CONSROE, P., ROESKE, W.R. & YAMAMURA, H.I. (1997). AM630 is a competitive cannabinoid receptor antagonist in the guinea pig brain. Life Sci., 61, PL115PL118.
  • HSIEH, C., BROWN, S., DERLETH, C. & MACKIE, K. (1999). Internalization and recycling of the CB1 cannabinoid receptor. J. Neurochem., 73, 493501.
  • HUFFMAN, J.W., LIDDLE, J., YU, S., AUNG, M.M., ABOOD, M.E., WILEY, J.L. & MARTIN, B.R. (1999). 3-(1′,1′-Dimethylbutyl)-1-deoxy-delta8-THC and related compounds: synthesis of selective ligands for the CB2 receptor. Bioorg. Med. Chem., 7, 29052914.
  • IWASE, K., MIYANAKA, K., SHIMIZU, A., NAGASAKI, A., GOTOH, T., MORI, M. & TAKIGUCHI, M. (2000). Induction of endothelial nitric-oxide synthase in rat brain astrocytes by systemic lipopolysaccharide treatment. J. Biol. Chem., 275, 1192911933.
  • IZZO, A.A., FEZZA, F., CAPASSO, R., BISOGNO, T., PINTO, L., IUVONE, T., ESPOSITO, G., MASCOLO, N., DI MARZO, V. & CAPASSO, F. (2001). Cannabinoid CB1-receptor mediated regulation of gastrointestinal motility in mice in a model of intestinal inflammation. Br. J. Pharmacol., 134, 563570.
  • IZZO, A.A., MASCOLO, N., BORRELLI, F. & CAPASSO, F. (1999a). Defaecation, intestinal fluid accumulation and motility in rodents: implications of cannabinoid CB1 receptors. Naunyn-Schmiedeberg's Arch. Pharmacol., 359, 6570.
  • IZZO, A.A., MASCOLO, N., PINTO, L., CAPASSO, R. & CAPASSO, F. (1999b). The role of cannabinoid receptors in intestinal motility, defaecation and diarrhea in rats. Eur. J. Pharmacol., 384, 3742.
  • JEON, Y.J., YANG, K.H., PULASKI, J.T. & KAMINSKI, N.E. (1996). Attenuation of inducible nitric oxide synthase gene expression by delta 9-tetrahydrocannabinol is mediated through the inhibition of nuclear factor- kappa B/Rel activation. Mol. Pharmacol., 50, 334341.
  • LAGNEUX, C. & LAMONTAGNE, D. (2001). Involvement of cannabinoids in the cardioprotection induced by lipopolysaccharide. Br. J. Pharmacol., 132, 793796.
  • LOPEZ-REDONDO, F., LEES, G.M. & PERTWEE, R.G. (1997). Effects of cannabinoid receptor ligands on electrophysiological properties of myenteric neurones of the guinea-pig ileum. Br. J. Pharmacol., 122, 350354.
  • MACNAUGHTON, W.K., VAN SICKLE, M.D., KEENAN, C.M., CUSHING, K., MACKIE, K. & SHARKEY, K.A. (2004). Distribution and function of the cannabinoid receptor-1 in the modulation of ion transport in the guinea pig ileum: relationship to capsaicin-sensitive nerves. Am. J. Physiol. Gastrointest. Liver Physiol., 286, 68636871.
  • MALAN JR, T.P., IBRAHIM, M.M., DENG, H., LIU, Q., MATA, H.P., VANDERAH, T., PORRECA, F. & MAKRIYANNIS, A. (2001). CB2 cannabinoid receptor-mediated peripheral antinociception. Pain, 93, 239245.
  • MARTINEZ-CUESTA, M.A., ESPLUGUES, J.V. & WHITTLE, B.J. (1996). Modulation by nitric oxide of spontaneous motility of the rat isolated duodenum: role of tachykinins. Br. J. Pharmacol., 118, 13351340.
  • MATSUDA, L.A., LOLAIT, S.J., BROWNSTEIN, M.J., YOUNG, A.C. & BONNER, T.I. (1990). Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature, 346, 561564.
  • MOLINA-HOLGADO, F., MOLINA-HOLGADO, E., GUAZA, C. & ROTHWELL, N.J. (2002). Role of CB1 and CB2 receptors in the inhibitory effects of cannabinoids on lipopolysaccharide-induced nitric oxide release in astrocytes cultures. J. Neurosci. Res., 67, 829836.
  • MOLINA-HOLGADO, F., PINTEAUX, E., MOORE, J.D., MOLINA-HOLGADO, E., GUAZA, C., GIBSON, R.M. & ROTHWELL, N.J. (2003). Endogenous interleukin-1 receptor antagonist mediates anti-inflammatory and neuroprotective actions of cannabinoids in neurons and glia. J. Neurosci., 23, 64706474.
  • MUNRO, S., THOMAS, K.L. & ABU-SHAAR, M. (1993). Molecular characterization of a peripheral receptor for cannabinoids. Nature, 365, 6165.
  • ORTEGA, M.P., GARCIA, M.C., GIJON, M.A., DE CASA-JUANA, M.F., PRIEGO, J.G., SANCHEZ CRESPO, M. & SUNKEL, C. (1990). 1,4-Dihydropyridines, a new class of platelet-activating factor receptor antagonists: in vitro pharmacologic studies. J. Pharmacol. Exp. Ther., 255, 2833.
  • PALMER, S.L., THAKUR, G.A. & MAKRIYANNIS, A. (2002). Cannabinergic ligands. Chem. Phys. Lipids, 121, 319.
  • PERTWEE, R.G., FERNANDO, S.R., NASH, J.E. & COUTTS, A.A. (1996). Further evidence for the presence of cannabinoid CB1 receptors in guinea pig small intestine. Br. J. Pharmacol., 18, 21992205.
  • PERTWEE, R.G. & ROSS, R.A. (2002). Cannabinoid receptors and their ligands. Prostagland. Leukotr. Essent. Fatty Acids, 66, 101121.
  • PINTO, L., IZZO, A.A., CASCIO, M.G., BISOGNO, T., HOSPODAR-SCOTT, K., BROWN, D.R., MASCOLO, N., DI MARZO, V. & CAPASSO, F. (2002). Endocannabinoids as physiological regulators of colonic propulsion in mice. Gastroenterology, 123, 227234.
  • PONS, L., DROY-LEFAIX, M.T., BRAQUET, P. & BUENO, L. (1991). Myoelectric intestinal disturbances in Escherichia coli endotoxic shock in rats. Involvement of platelet-activating factor. Lipids, 26, 13591361.
  • QUARTILHO, A., MATA, H.P., IBRAHIM, M.M., VANDERAH, T.W., PORRECA, F., MAKRIYANNIS, A. & MALAN JR, T.P. (2003). Inhibition of inflammatory hyperalgesia by activation of peripheral CB2 cannabinoid receptors. Anesthesiology, 99, 955960.
  • REBOLLAR, E., ARRUEBO, M.P., PLAZA, M.A. & MURILLO, M.D. (2002). Effect of lipopolysaccharide on rabbit small intestine muscle contractility in vitro: role of prostaglandins. Neurogastroenterol. Motil., 14, 633642.
  • RICE, A.S., FARQUHAR-SMITH, W.P. & NAGY, I. (2002). Endocannabinoids and pain: spinal and peripheral analgesia in inflammation and neuropathy. Prostagland. Leukotr. Essent. Fatty Acids, 66, 243256.
  • ROSELL, S., AGURELL, S. & MARTIN, B. (1976). Effects of cannabinoids on isolated smooth muscle preparations. In: Marijuana, Chemistry, Biochemistry & Cellular Effects, ed. Nahas, G.G.E. & Idanpaan-Heikkilapp, J.E. pp. 397406. Berlin: Springer-Verlag.
  • ROSS, R.A., COUTTS, A.A., MCFARLANE, S.M., ANAVI-GOFFER, S., IRVING, A.J., PERTWEE, R.G., MACEWAN, D.J. & SCOTT, R.H. (2001). Actions of cannabinoid receptor ligands on rat cultured sensory neurones: implications for antinociception. Neuropharmacology, 40, 221232.
  • SHIRE, D., CALANDRA, B., BOUABOULA, M., BARTH, F., RINALDI-CARMONA, M. & CASE FERRARA, P. (1999). Cannabinoid receptor interactions with the antagonists SR141716A and SR144528. Life Sci, 65, 627635.
  • SHOOK, J.E. & BURKS, T.F. (1989). Psychoactive cannabinoids reduce gastrointestinal propulsion and motility in rodents. J. Pharmacol. Exp. Ther., 249, 444449.
  • SOUTHAN, G.J., SZABO, C. & THIEMERMANN, C. (1995). Isothioureas: potent inhibitors of nitric oxide synthases with variable isoform selectivity. Br. J. Pharmacol., 114, 510516.
  • STORR, M., GAFFAL, E., SAUR, D., SCHUSDZIARRA, V. & ALLESCHER, H.D. (2002). Effect of cannabinoids on neural transmission in rat gastric funds. Can. J. Physiol. Pharmacol., 80, 6776.
  • TAN, D., ROUGEOT, C., DAVISON, J.S. & MATHISON, R. (2000). The carboxamide feG(NH2) inhibits endotoxin perturbation of intestinal motility. Eur. J. Pharmacol., 409, 203205.
  • THEODOROU, V., FIORAMONTI, J. & BUENO, L. (1993). Recombinant interleukin-1 receptor antagonist protein prevents sensitization and intestinal anaphylaxis in guinea pigs. Life Sci., 53, 733738.
  • TYLER, K., HILLARD, C.J. & GREENWOOD-VAN MEERVELD, B. (2000). Inhibition of small intestinal secretion by cannabinoids is CB1 receptor-mediated in rats. Eur. J. Pharmacol., 409, 207211.
  • VALLE, L., PUIG, M.M. & POL, O. (2000). Effects of mu-opioid receptor agonists on intestinal secretion and permeability during acute intestinal inflammation in mice. Eur. J. Pharmacol., 389, 235242.
  • WALTERS, M.N. & WILLOUGHBY, D.A. (1965). Indomethacin, a new anti-inflammatory drug: its potential use as a laboratory tool. J. Pathol. Bacteriol., 90, 641648.
  • WIRTHLIN, D.J., CULLEN, J.J., SPATES, S.T., CONKLIN, J.L., MURRAY, J., CAROPRESO, D.K. & EPHGRAVE, K.S. (1996). Gastrointestinal transit during endotoxemia: the role of nitric oxide. J. Surg. Res., 60, 307311.
  • ZHANG, H.Q., FAST, W., MARLETTA, M.A., MARTASEK, P. & SILVERMAN, R.B. (1997). Potent and selective inhibition of neuronal nitric oxide synthase by N omega-propyl-L-arginine. J. Med. Chem., 40, 38693870.